Histone deacetylase (HDAC) inhibitors demonstrate dual therapeutic benefits in both preventing graft-versus-host disease (GVHD) and preserving graft-versus-leukemia (GVL) effects, as evidenced by recent research (165). Here, HDAC9 is linked to graft versus host disease.